1-3 of 3
Melanie Grant
Close
Sort by
Journal Articles

Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT

Clinical Trials & Observations
Hannah Kinoshita, Kenneth R. Cooke, Melanie Grant, Maja Stanojevic, C. Russell Cruz, Michael Keller, Maria Fernanda Fortiz, Fahmida Hoq, Haili Lang, A. John Barrett, Hua Liang, Jay Tanna, Nan Zhang, Abeer Shibli, Anushree Datar, Kenneth Fulton, Divyesh Kukadiya, Anqing Zhang, Kirsten M. Williams, Hema Dave, Jeffrey S. Dome, David Jacobsohn, Patrick J. Hanley, Richard J. Jones, Catherine M. Bollard
Journal: Blood Advances
Blood Adv (2022) 6 (8): 2520–2534.
https://doi.org/10.1182/bloodadvances.2021006831
Published: 2022
Includes: Supplemental data
Journal Articles

Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma

Clinical Trials & Observations
Hema Dave, Madeline Terpilowski, Mimi Mai, Keri Toner, Melanie Grant, Maja Stanojevic, Christopher Lazarski, Abeer Shibli, Stephanie A. Bien, Philip Maglo, Fahmida Hoq, Reuven Schore, Martha Glenn, Boyu Hu, Patrick J. Hanley, Richard Ambinder, Catherine M. Bollard
Journal: Blood Advances
Blood Adv (2022) 6 (2): 473–485.
https://doi.org/10.1182/bloodadvances.2021005343
Published: 2022
Includes: Supplemental data
Journal Articles

Developing T-cell therapies for lymphoma without receptor engineering

Melanie Grant, Catherine M. Bollard
Journal: Blood Advances
Blood Adv (2017) 1 (26): 2579–2590.
https://doi.org/10.1182/bloodadvances.2017009886
Published: 2017